value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. [published online April 3, 2018]. J Med Econ. doi: 10.1080/13696998.2018.1457533.

This health economic analysis predicted that, compared with use of supportive care, erenumab treatment will reduce the direct and indirect costs associated with migraine and increase quality-adjusted life-years for patients who have previously experienced treatment failure with at least 1 preventive migraine treatment.